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Abstract
Objectives—To describe initial registration characteristics of adult and pediatric TB patients at a
large, public, integrated TB and HIV clinic in Lilongwe, Malawi, between January 2008 –
December 2010.
Methods—Routine data on TB patient category and TB type, stratified by HIV and ART status,
were used to explore differences in proportions among TB-only, TB/HIV co-infected patients not
on ART, and TB/HIV co-infected patients on ART using Chi-square tests.. Trends over time
illustrate strengths and weaknesses of integrated service provision.
Results—Among 10,143 adults, HIV ascertainment and ART uptake were high and increased
over time. The proportion of relapse was highest among those on ART (5%). The proportion of
smear-positive pulmonary TB (PTB) was highest among HIV-negative TB patients (34.9%);
extra-pulmonary TB (EPTB) was lowest among TB-only (16.2%). Among 338 children <15 years,
EPTB and smear-positive PTB were more common among TB-only patients. Time trends showed
significant increases in the proportion of adults with smear-positive PTB and the proportion of
adults already on ART before starting TB treatment. However, some co-infected patients still
delay ART initiation.
Conclusions—HIV ascertainment and ART uptake among co-infected patients is successful and
improving over time. However, delays in ART initiation indicate some weakness linking TB/HIV
patients into ART during TB follow-up care. Improved TB diagnostics and screening efforts,
especially for pediatric patients, may help improve quality care for co-infected patients. These
results may aid efforts to prioritize TB and HIV prevention, education, and treatment campaigns
for specific populations.
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Introduction
Malawi, similar to its sub-Saharan neighbors, faces the burden of fighting simultaneous HIV
and TB epidemics. In 2009, Malawi reported 37,000 TB cases to the WHO with a case
detection rate of 49% of smear-positive infections (WHO 2011), below the STOP TB target
of 70% smear-positive case detection (WHO 2008). HIV prevalence in Malawi, is 12%:
323,638 people were alive on ART (62% female) as of December, 30th, 2011, representing
approximately 65% ART coverage nationwide (Government of Malawi Ministry of Health
2011). Among TB patients, approximately 67% are HIV co-infected (Government of
Malawi Ministry of Health 2011); 43% of newly diagnosed TB cases are HIV-infected and
already on ART (Ministry of Health and Population Malawi 2011).
Previous studies from the region describe TB prevention, screening or treatment among
HIV-infected patients (Abdool Karim et al. 2010; Harries et al. 2010; Khan et al. 2010;
Lawn et al. 2006; Lawn & Wood 2011) and highlight efforts at TB and HIV integration
(Harries et al. 2006; Harries et al. 2002a; Harries et al. 2004b; Uyei et al. 2011), including
within Malawi (Chimzizi & Harries 2007; Harries et al. 2004a, 2009a; Libamba et al. 2005,
2006; Zachariah et al. 2005). However, fewer studies describe patient demographic
characteristics, including HIV testing and ART uptake, from the perspective of TB care
settings (Chimzizi et al. 2004; Lawn et al. 2011a,b) that may serve as an entry point of care
for co-infected patients. To the authors’ knowledge, no recent study describes TB patient
characteristics at TB treatment initiation based on both HIV and ART status, including those
who are not HIV co-infected.
Therefore, we aim to fill a gap in the literature and complement previous research by
describing baseline characteristics, HIV ascertainment, and ART status of adult and
pediatric patients at TB treatment registration within an integrated HIV/TB care setting.
Lighthouse Trust’s Martin Preuss Centre (MPC) is the largest integrated public TB/HIV
clinic in Malawi, providing an opportunity to describe patient characteristics that are
expected to be different at an integrated site, including more complete HIV status
ascertainment and ART information at TB registration. We use routine, programmatic, TB
case data from MPC between January 2008 – December 2010 to explore differences in TB
patient category as defined by the National TB Control Program (NTP) (new, relapse,
failure, retreatment after default, other) and TB type (extrapulmonary (EPTB) and
pulmonary (PTB)) among three patient categories: 1) non-HIV-infected TB patients (TB-
only); 2) HIV-infected TB patients not on ART at TB treatment initiation (TB/HIV); and 3)
HIV-infected TB patients already on ART prior to TB treatment initiation (TB/ART).
Trends over the 3-year time period were examined to help provide critical information for
program and policy planning. The results from this descriptive study may aid understanding
about the current TB epidemic, inform future TB/HIV integration efforts, and lead to
improvements in TB control programs and policies.
Methods
Setting
Lighthouse Trust works in close coordination with the Ministry of Health (MoH) and
District Health Office (DHO) to operate two large integrated HIV testing, treatment and care
clinics in Lilongwe, Malawi: Lighthouse Clinic (LH) on the campus of Kamuzu Central
Hospital and the Martin Preuss Center (MPC) located near the central bus station on the
campus of Bwaila Maternity Hospital. Combined, Lighthouse is the largest provider of ART
in Malawi’s central region with over 16,000 patients alive on ART: approximately 7,500 at
LH and 8,500 at MPC. LH and MPC screen all patients for TB at each clinic visit and
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provide TB treatment; neither clinic conducts intensive TB case finding activities. LH cares
only for HIV-infected patients.
MPC opened in late 2006 as a purposeful TB/HIV integrated care clinic. In addition to its
HIV-related services, MPC currently houses the largest TB registration centre in Malawi
with approximately 3,500 TB patients and 3900 TB suspects, annually. Nationwide, there
are 70 TB registration sites including 20 in Central Region and 5 in Lilongwe District
(Government of Malawi Ministry of Health 2011). Patients must register and begin
treatment at one of these sites but may elect to continue TB treatment at the registration site
or another peripheral health facility. MPC’s integrated TB/HIV model was described in
detail previously (Phiri et al. 2011).
At MPC’s TB treatment registration, more than 95% of TB patients have known HIV status
at TB treatment initiation in large part due to its opt-out HIV testing policy for TB suspects
and patients. All HIV-positive TB patients are eligible to start ART according to national
guidelines, and co-infected patients receive both TB and HIV clinical care at MPC. Between
50-60% of HIV-positive TB patients initiate ART and complete their TB treatment at MPC.
Other patients initiate TB treatment at MPC but complete TB treatment at one of 18
peripheral sites in Lilongwe. The ART status of patients who do not initiate ART at MPC is
unknown.
At MPC, as with other public TB clinics in Malawi, diagnosis of TB for adults and children
is based most commonly on clinical examination, sputum smear microscopy, and chest
radiography. Extrapulmonary (EPTB) may also be diagnosed bacteriogically or
histopathologically. The Malawi NTP control program classifies patients into 5 patient
categories (Malawi Ministry Of Health 2007): 1) new: patients with no previous TB
treatment; 2) relapse: cured or completed treatment prior to becoming smear-positive; 3)
failure: remained sputum smear-positive at five months or more during first-line treatment;
4) re-treatment after default (RAD): interrupted treatment for more than two months and
returned with smear-positive TB; and 5) other, which may include chronic re-treatment TB
patients and patients with recurrent smear-negative pulmonary TB (Tweya et al. 2011).
Once diagnosed with TB, patient details are recorded in the national TB registers by the
district TB officer. New and re-treatment TB cases are treated in accordance with standard
WHO regimens (WHO 2003) consisting of rifampicin (R), isoniazid (H), pyrazinamide (Z)
and ethambutol (E).
Study design and population
This retrospective cohort study of all TB patients used routine program data from both TB
registers and patient treatment cards collected from January 2008 to December 2010 at
MPC. All adults and children at MPC diagnosed with active TB according to national
guidelines were eligible.
Data collection
All patient demographic and ART-related information was extracted from MPC’s real-time
electronic data system (EDS). TB data from paper registers, including TB registration
number; registration date; TB type (EPTB or PTB); patient category; initial sputum
microscopy results; HIV status (positive, negative, unknown); ART status (ART before TB
treatment; ART at or after TB treatment initiation; not on ART) and treatment regimen, was
back entered into an offline Access database and matched with demographic and ART
information using patient identification codes. Missing or incomplete TB data in the register
were filled or verified using individual patient mastercards. CD4 test results were included
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from the EDS when available using the closest recorded CD4 test within 90 days of TB
registration.
Data Analysis
Data analysis, stratified by age (children <15 years and adults ≥15 years) was conducted
using Access 2003 and STATA 9.2 (StataCorp 2005). Frequency tables and univariate
analysis detected problems in the dataset, issues of linearity, or unusual outliers; data clerks
corrected inconsistencies. Chi square tests of proportions were used to determine differences
over time and between the three groups across variables of interest: 1) non-HIV-infected TB
patients (TB-only); 2) HIV-infected TB patients not on ART at TB treatment initiation (TB/
HIV); 3) HIV-infected TB patients already on ART prior to TB treatment initiation (TB/
ART). Statistical significance was defined as p ≤ 0.05.
Ethics approval
The Malawi National Health Science Research Committee provided general blanket
approval for the collection and use of routine programmatic data for monitoring and
evaluation at Lighthouse Clinics for 2011, including this study.
Results
Adults ≥ 15 years
Of the 10,595 adult TB patients aged 15 or older, 5985 (59%) were male. The largest
proportion of patients was between the ages of 25-34 (38.4%). Most patients (89.5%) were
new TB cases. Of the 10,143 patients (96%) with recorded HIV information, 60.2% were
tested before TB treatment. The majority (66.5%) of adult TB patients were HIV co-
infected: 64% of men and 70% of women. Among the 6747 HIV+ patients, 3071 (44.7%)
had a recorded ART start date: 39.5% started before TB treatment, 55.6% started during TB
treatment, and 4.9% started after TB treatment. Among HIV+ patients, only 792 (11.7%)
had a recorded CD4 count within 90 days of TB registration. Of all adults, 48.6% chose to
start and complete TB treatment at MPC. Among TB/ART patients, 2228 (72.5%) were
managed at MPC. The number of TB patients managed at MPC decreased over time: 4271,
3263, and 3061 adult patients registered in 2008, 2009, and 2010, respectively.
Patient demographics differed between the TB-only, TB/HIV, and TB/ART groups (Table
1). Men comprised 63% of the TB-only group; 58.4% of TB/HIV; and 50.2% of TB/ART
patients (p <0.001). Age varied significantly across groups (p <0.001). TB-only patients
were more likely to be under 25 (20.9%) while a higher proportion of TB/HIV (73.2%) and
TB/ART (73.4%) patients were concentrated in the middle age groups, ages 25-45, as
compared to TB-only (47%). TB-only patients were also more likely to be 45 years or older
(32.2%) as compared to TB/HIV (16.2%) and TB/ART (17.6%) patients.
Relapse was higher among TB/ART (5.0%) than TB-only patients (3.2%) and TB/HIV
patients(2.6%) (p <0.001). TB/ART patients had the highest proportion of “other” patients
(13%) (p <0.001) , patients who are more likely to be mis-categorized re-treatment cases and
HIV co-infected (Tweya et al. 2011). EPTB was most common among TB/ART (26.9%)
and less common among TB/HIV (20.7%) and TB-only (16.2%) (p < 0.001). Smear-positive
PTB was significantly higher among TB-only patients (34.9%) than those co-infected (p
<0.001). Across all 3 groups, approximately 50% were smear-negative PTB. Among those
with CD4, there was no significant relationship between TB classification and CD4 count
(p= 0.532) (data not shown).
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Considering trends over time (Table 3), TB classification varied over time (p<0.001): the
proportion of smear-positive PTB increased from 24.6% to 37.0% of all patients over time.
EPTB cases also rose slightly from 18.8% to 22.5% over the same 3-year period. According
to the standard ARV status categories at TB registration, the proportion of TB/ART patients
increased significantly (p< 0.001) between 2008 (19.3%) and 2010 (48.6%). Among the
74% of patients with a specific ART start date (N=2,229), there were significant changes in
the timing of ART initiation. Between 2008 and 2010, those started on ART within 30 days
of TB treatment increased from 1.4% to 57.0% while the proportion that started ART 60 or
more days after TB treatment initiation dropped dramatically from 67.7% to 10.3%
(p<0.001). HIV co-infection (p=0.592) and gender (p=0.789) did not vary significantly over
time.
Children <15 years
Of the 364 children, 338 children had HIV status information and were included in this
analysis (Table 2). Of 338, 49.7% were tested before seeking TB treatment and 43.4% of all
tested were HIV-positive. About half (49.7%) were male and 29.3% were under age 5. Most
children (94.4%) were new TB patients; 4.8% were classified as “other”. Among all 299
with known TB classification, 18.1% were diagnosed with EPTB, 69.9% with smear-
negative PTB, and 12% had smear-positive PTB. Among the 148 HIV+ patients, 66 (44.6%)
had a recorded ART start date: 15 children started ART before TB treatment, 50 children
started ART during TB treatment, and one child started ART after TB treatment. Among
HIV+ patients, 25 had a recorded CD4 count within 90 days of TB registration. Of all
pediatric patients, 58.9% started and completed TB treatment at MPC; among TB/ART
patients, 55 (83.3%) were managed at MPC. The number of pediatric TB patients varied
over time: 151, 72, and 115 patients registered in 2008, 2009, and 2010, respectively.
Among children, TB baseline characteristics differed among TB-only, TB/HIV, and TB/
ART groups. EPTB was highest among children with TB-only (20.7%), as compared to
14.7% of TB/HIV and 14.3% of TB/ART patients. Smear-negative PTB was the most
common type of TB across all groups: 62% of TB-only; 81% of TB/HIV and 79% of TB/
ART children. Smear positive TB was less frequent with 17.8% of TB-only as compared to
4.3% of TB/HIV and 7.1% of TB/ART children. There were no other significant differences
among children based on their TB, HIV, and ART status nor significant trends over time
(Table 3).
Discussion
To our knowledge, this is one of the first papers to describe the treatment initiation
characteristics of both adult and pediatric TB patients at a large, public, integrated TB/HIV
management setting, including exploration of trends over time. We note several differences
between TB patient groups based on TB type and patient category as well as by HIV and
ART status.
First, this study shows both strengths and weaknesses in TB/HIV integration at MPC over
time. HIV ascertainment was highly successful: during this 3-year period, the proportion
with known HIV status remained between 95-97%. In comparison, in 2011 the national HIV
ascertainment rate among TB patients was ranged from 83-90% (Government of Malawi
Ministry of Health 2011). The consistency of HIV ascertainment demonstrates MPC’s
successful integration of HIV testing and lends further support for a provider-initiated, opt-
out HIV testing approach within TB care settings (Harries et al. 2009b). Time trends among
adults also reveal significant increases in the proportion of patients already on ART, a
positive finding that likely reflects both MPC’s emphasis on TB screening among ART
patients as well as the nation-wide scale up of ART (Ministry of Health and Population
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Malawi 2011). There was also a significant and positive increase in earlier initiation of co-
infected patients onto ART: between 2008 and 2010, the proportion of co-infected adults at
MPC who started ART within 30 days of TB treatment initiation increased dramatically
from 1.4% to 57%. This shift in treatment timing was likely influenced by results from
research on early mortality among TB/HIV patients in Malawi (Zachariah et al. 2007) and
subsequent guideline changes that recommended earlier ART initiation among those co-
infected (Ministry of Health Malawi 2008). Despite successes, some TB patients still delay
ART initiation. In 2008, more than 67% of co-infected patients delayed ART until after the
intensive phase, 60 days, after TB treatment; by 2010, only 10.3% of co-infected patients
started as late. Follow-up exploration (not shown) found that the 78 patients, or 10%, who
did not start ART within 60 days were more likely to be male (72%) (p< 0.05) and within
the age group 25-34 years (47%) (p<0.05). Although significant progress is clear, continued
delayed uptake may indicate persistent weaknesses in linking TB/HIV patients into ART
during TB follow-up care as well as continued patient hesitancy or fears about concurrent
treatment (Phiri et al. 2011) which merit attention. Lastly, the overall proportion of TB
patients with smear-positive TB increased over time. No new laboratory technology or other
systematic changes were implemented at MPC during this period, and it is unknown whether
case detection improved or whether there was an actual increase in the proportion of smear-
positive patients.
Second, MPC’s integrated service model also allows for identification of differences in TB
patient category that exist based on HIV and ART status. First, as expected, the proportion
of new TB patients, as opposed to all other categories, was highest among TB-only patients.
Second, and more interestingly, the proportion of relapse among MPC patients was highest
among those on ART: 3.2% of TB-only, 2.6% of TB/HIV, and 5% of TB/ART patients were
categorized as relapse. Although distinguishing between relapse and re-infection would
require molecular diagnostics beyond the capability of MPC, this finding is interesting in
comparison to a study on recurrent TB in Karonga, Malawi. Crampin et al. (2010) found no
significant difference in proportions of relapse among patients based on HIV status, but
found re-infection highest among those TB/HIV co-infected. The role of ART was not
considered in the Karonga study, but it may have played a role among MPC patients.
Among MPC patients, immune reconstitution inflammatory syndrome (IRIS) or ART-
associated TB may have played a role in development or redevelopment of active TB among
HIV-infected patients (Lawn et al. 2008); 94 MPC ART patients developed active TB within
6 weeks of starting ART. Moreover, lack of adherence to either TB or ART regimens, due to
increased pill burdens, side effects, or perceptions of regimen complexity on the part of
patients or clinicians, may increase the likelihood of TB recurrence among co-infected
patients (Panjabi et al. 2007). No additional information on treatment adherence or TB
recurrence was available at the time of the study.
Third, TB patient baseline characteristics differ based on HIV and ART status. First, the
proportion of smear-positive PTB was highest among TB-only patients (34.9%) as HIV co-
infected patients are more likely to have smear-negative PTB or EPTB (Harries 1990; Shafer
et al. 1991) while smear-negative PTB was similar across all patient groups. Also the
proportion of EPTB was higher among TB/HIV (20.7%) and TB/ART (26.9%) patients than
among TB-only adults (16.2%), confirming previous research (Corbett et al. 2006). In post
hoc analysis considering whether time on ART was a factor in predicting EPTB vs. PTB
classification (data not shown), no significant association between time on ART and TB
classification was found. Lastly, although gender did not vary significantly between groups
nor show changes over time, women are the minority of TB-only (37%); TB/HIV (41.6%)
and TB/ART (49.8%) patients at MPC although 62% of nationwide ART patients are female
(Government of Malawi Ministry of Health 2011) confirming previous studies on the
disproportionate number of men infected with TB in Malawi (Boeree et al. 2000).
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Fourth, our study contributes information on TB characteristics among children,
complementing and updating previous research in Malawi (Harries et al. 2002b,1997;
Kiwanuka et al. 2001; Poerksen et al. 2008). Among MPC children, boys and girls are
infected in equal proportions suggesting household infection in contrast to adult men who
may face external occupational risk areas outside of the home. Also, the vast majority of
children in all categories were smear-negative PTB: 61.5% of TB-only; 81.0% of TB/HIV,
and 78.6% of TB/ART children. The proportion of EPTB also differed between groups:
20.7% of TB-only pediatric patients as compared to about 14% of co-infected children
regardless of ART status. These findings may be muddled by the inherent complications of
collecting sputum from young children (Zar et al. 2005) and may indicate the need for
improved diagnostic tools such as GenXpert that are currently unavailable at MPC.
Screening of children could also improve if smear-positive, adult TB patients brought in
household contacts, including children, for testing and preventative treatment as
recommended by the NTP. However, funding constraints prevent or delay active follow-up
of smear-positive patients, limiting the effectiveness of efforts to combat household
exposure. Lastly, time trends of increased proportions of patients on ART before TB
treatment apparent among adults is not replicated among children, possibly suggesting that
there are weaknesses in TB screening among children on ART or that TB-IRIS may be less
common.
Limitations
This descriptive study should be considered with the following limitations. Among all
patients, 478 (4.4%), 26 children and 451 adults, did not have HIV status information and
were excluded from the baseline characteristics analysis but included in the trends over time.
Also, some discrepancies in the paper-based records could not be reconciled, excluding 73
patients. There were few patients with CD4 results and ART adherence data, preventing
consideration of these factors. Also, many patients who started ART at a clinic other than
MPC did not provide an exact ART start date, potentially biasing the time trends results of
ART initiation timing. Furthermore, we grouped patients who were on ART for any length
of time before TB treatment, reducing the ability to determine if time on ART could have
played a role in TB characteristics at TB treatment registration. Lastly, although MPC is
Malawi’s largest TB registration site, the findings may be most useful for other large
burden, integrated TB/ART clinics in urban areas.
Conclusions
We described patient characteristics at TB registration at MPC, the largest integrated public
TB/HIV clinic in Malawi, among three groups: TB-only; HIV-infected TB patients not on
ART (TB/HIV); and HIV-infected TB patients already on ART prior (TB/ART). We found
that new TB patients were more likely to be TB-only patients while the proportion of relapse
was highest among TB/ART patients. Smear-positive TB was highest among TB-only while
the proportion of EPTB was higher among both co-infected groups. Most children were
smear-negative PTB with higher proportion of TB-only children diagnosed with EPTB.
Time trends showed consistently high ascertainment of HIV status among TB registrants
and significant improvements in early ART initiation among those co-infected.
In response to the study findings and to strengthen future research, MPC is undertaking
several steps to improve quality care. In early 2012, the established electronic data system
(EDS) for ART will be expanded to include critical information for management of patients
infected with TB, including HIV/TB co-infected patients. Not only will the EDS component
reduce the occurrence of missing data, but the system will include reminders for providers to
initiate co-infected patients not yet on ART and include TB patient contact information for
follow-up testing and treatment for household members, especially children. MPC is also
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conducting additional refresher training with professional staff and increasing both
monitoring and supervision efforts to continue improving the integrated care model.
These findings also suggest several areas for additional operations research at MPC or other
low-resource, integrated care settings. First, delays in ART initiation among some patients
are a cause for concern and weaknesses in the linkages between TB and ART treatment
initiation should be examined. Second, the increase in the proportion of patients with smear-
positive TB suggests that increased efforts at infection control may be necessary to reduce
the spread of TB within the integrated clinic setting. Third, future quantitative studies should
look at the associations between TB and ART treatment adherence in the development and
diagnosis of TB as well as examine factors that influence ART initiation and uptake among
co-infected patients. Lastly, exploration of the factors that influence ART uptake and timing
among co-infected patients would add considerably to understanding of the drivers of and
deterrents to quality, integrated care.
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Table 1
Differences in proportions between adult TB-only, TB/HIV, and TB/ART patients
HIV-Negative HIV-Positive
TB TB/HIV TB/ART All TB adults
N=3395 (33.5) N=5561 (54.8) N=1187 (11.7) 10,143
% # % # % # % #
Patient category (10,111)***
New 90.4 3063 90.8 5027 81.1 961 89.5 9051
Relapse 3.2 108 2.6 141 5.0 59 3.1 308
RAD 0.7 23 0.5 25 0.6 7 0.5 55
Failure 0.2 8 0.1 7 0.1 1 0.2 16
Other 5.5 186 6.1 338 13.3 157 6.7 681
TB Classification (9,889)***
EPTB 16.2 541 20.7 1117 26.9 312 19.9 1970
Smear-negative PTB 48.9 1628 55.7 3005 50.0 582 52.7 5215
Smear-positive PTB 34.9 1163 23.1 1272 27.3 269 27.3 2704
TB treatment (4,546) ***
RHZE 94.2 1326 93.8 2204 88.1 685 92.9 4225
Isoniazid 0.3 4 0.3 6 0.1 1 0.2 11
ZHRS 0.1 1 0.1 2 0.1 1 0.1 4
RHZE+S 5.4 76 5.2 122 10.5 83 6.2 281
RHZ+s 0 0 0.7 16 1.1 9 0.6 25
Gender***
Male 63.0 2139 58.4 3250 50.2 596 59.0 5985
Female 37.0 1256 41.6 2311 49.8 591 41.0 4158
Age***
15-24 20.9 709 10.6 589 9.0 107 13.9 1405
25-34 30.1 1021 43.2 2401 40.2 477 38.4 3899
35-44 16.9 572 30.0 1668 33.2 394 26.0 2634
≥45 32.2 1093 16.2 903 17.6 209 21.7 2205
Registration year ***
2008 40.3 1367 45.2 2516 11.9 141 39.7 4024
2009 31.1 1055 29.6 1645 38.0 451 31.0 3151
2010 28.7 973 25.2 1400 50.1 595 29.3 2968
*p<0.05
**p<0.01;
***p<0.001. Parentheses are used to show N for categories with missing data.
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Table 2
Differences in proportions between pediatric TB-only, TB/HIV, and TB/ART patients under age 15
HIV-Negative HIV-Positive
TB TB/HIV TB/ART All children
N=190 (56.2) n=133 (39.4) N=15 (4.44) N=338
% # % # % # % #
Patient category (337)
New 96.8 184 91.7 122 85.7 12 94.4 318
Relapse 0.5 1 0.0 0 0.0 0 0.3 1
RAD 0.5 1 0.0 0 0.0 0 0.3 1
Failure 0.5 1 0.0 0 0.0 0 0.3 1
Other 1.6 3 8.3 11 14.3 2 4.8 16
TB Classification (299)***
EPTB 20.7 35 14.7 17 14.3 2 18.1 54
Smear-negative PTB 61.5 104 81.0 94 78.6 11 69.9 209
Smear-positive PTB 17.8 30 4.3 5 7.1 1 12.0 36
TB treatment (158)
RHZE 98.0 93 100 52 100 11 98.7 156
Isoniazid 2.0 2 0 0 0 0 1.3 2
Age group*
<5 31.6 60 27.1 36 20 3 29.3 99
>=5 & <15 68.4 130 72.9 97 80.0 12 70.7 239
Gender
Male 50.0 95 47.4 63 66.7 10 49.7 168
Female 50.0 95 52.6 70 33.3 5 50.3 170
Registration year
2008 41.6 79 51.9 69 20.0 3 44.7 151
2009 21.1 40 20.3 27 33.3 5 21.3 72
2010 37.4 71 27.8 37 46.7 7 34.0 115
*p<0.05
**p<0.01;
***p<0.001. Parentheses are used to show N for categories with missing data.
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